Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Cholangiocarcinoma 2 Upper Tract Urothelial Carcinomas 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Papillomavirus Infections 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Hematologic Neoplasms 1 Glioma 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Ipilimumab 79 pembrolizumab 71 Nivolumab 68 aldesleukin 46 Cyclophosphamide 44 Interleukin-2 33 fludarabine phosphate 30 Vemurafenib 29 Dacarbazine 28 trametinib 25 fludarabine 25 dabrafenib 25 Temozolomide 21 Bevacizumab 15 Radiosurgery 14 binimetinib 12 Paclitaxel 12 Introns 12 Interferon alpha-2 12 Carboplatin 11 CTLA-4 Antigen 11 peginterferon alfa-2b 9 montanide ISA 51 9 encorafenib 9 cobimetinib 9 Radiotherapy 9 talimogene laherparepvec 8 atezolizumab 8 Sorafenib 8 spartalizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡